5 Key Takeaways
-
1
CMS proposes to increase physician payment for in-office laser trabeculoplasty, reflecting its importance in glaucoma treatment.
-
2
A 2021 survey revealed that 75% of US ophthalmologists prefer topical medication for POAG, yet most would choose laser trabeculoplasty for themselves.
-
3
The LiGHT trial showed that laser treatment slows glaucoma progression by 29% compared to eye drops, emphasizing its effectiveness.
-
4
CMS plans to increase the allowed amount for LTP from $235 in 2025 to $246 in 2026, recognizing higher indirect costs in office settings.
-
5
The introduction of Alcon’s Voyager DSLT device in 2025 aims to enhance the treatment of POAG and OHT with a more efficient laser procedure.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
